Innovation funding

In October 2024, the Ministry of Health, Welfare, and Sport decided to discontinue the "Subsidy scheme for promising care," which was implemented in 2019 to support the development of missing clinical and economic evidence for promising care that otherwise cannot be covered within basic health insurance. There are 28 ongoing projects, and some new projects will be awarded the subsidy in the 2025 round.

On October 14, 2024, the Institute for the Hospital Remuneration System (InEK) published the DRG catalog (Fallpauschalen-Katalog) with the list of DRGs and additional reimbursement categories (ZEs) for 2025. Three new DRGs were introduced in the endoscopy and ophthalmology fields.

In September 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects that received a subsidy under the "Subsidy scheme for promising care" in 2024 for research on the cost-effectiveness of cold plasma therapy for diabetic foot or venous leg wounds and intranasal mesenchymal stem cells in newborns with hypoxic-ischemic brain damage.

In July 2024, the Dutch Organization for Health Research and Development (ZonMw) awarded thirteen projects under the 2025 round of the Efficiency Research program, including one project on e-health, one project on extracorporeal treatments, one project in orthopedics, one project in neurology, one project in urology, two projects in obstetrics and gynecology, one project in radiotherapy and one project in the cardiovascular area.

In early July 2024, Dutch Organization for Health Research and Development (ZonMw) awarded seventeen projects under the Efficiency Research program, including four projects on e-health, two projects on diagnostic imaging techniques, two projects in orthopedics, one project on abdominal surgery, one project in gynecology, and one project in the cardiovascular area.

On July 10, 2024, the Dutch Organization for Health Research and Development (ZonMw) announced the submission of grant applications for research on patient-relevant outcomes and alternative forms of financing for innovative treatment under the Medical Specialist Care and Research (MedZO) program. The submission of grant applications will continue until October 15, 2024.

On June 21, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for healthcare research projects (eight topics) and clinical guidelines (three topics).

On April 25, 2024, the Ministry of Labor, Health, and Solidarity published an Order in the Official Journal of the French Republic setting the tariffs for digital medical devices with therapeutic functions covered within the early digital support (PECAN) scheme. The tariff for the manufacturer will include an initial lump sum of €435 per patient billable for up to 3 months and a subsequent monthly package of €38.30. The maximum amount of financial compensation is €780 per year per patient.

On March 31, 2024, the Ministry of Labor, Health, and Solidarity published a Decree in the Official Journal of the French Republic relating to the conditions of coverage of innovative IVD tests within the RIHN framework, which should facilitate the transition from the RIHN framework to regular reimbursement via the NABM Nomenclature.

In April 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects which received a subsidy under the "Subsidy scheme for promising care" in 2024 for research of targeted muscle reinnervation during leg amputation and thrombectomy by catheterization in adult patients with a high-risk pulmonary embolism.

On January 19, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decision recommending the transfer to standard care for another completed project. The project evaluated the web-based initial assessment tool SmED in outpatient emergency care.

On January 26, 2024, NHS England announced the third round of the Innovation Open Call, funded by the NHS Cancer Programme. All types of late-stage innovations aimed at early detection and diagnosis of cancer are eligible, including medical devices, in-vitro diagnostics, digital health solutions, and AI. Awarded projects will be 100% funded up to the total value of £4 million to produce and evaluate evidence in a real-world setting, supporting adoption and spread by providers, commissioners, and regulators. The application submission will be open on April 8, 2024.